Universal Health Services, Inc.
186.89USD
-1.2400 (-0.66%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on UHS.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $5.15▼ | $5.56 | 2 | 2 |
| Next quarter | $5.73▼ | $6.17 | 2 | 0 |
| Current year | $22.48▼ | $23.39 | 2 | 2 |
| Next year | $23.89▼ | $25.16 | 2 | 3 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $6.01 | $5.98 | -0.03 (-0.4%) |
| 2026-03-31 | $5.46 | $5.62 | +0.16 (+2.9%) |
| 2025-12-31 | $5.91 | $5.88 | -0.03 (-0.5%) |
| 2025-09-30 | $4.95 | $5.69 | +0.74 (+14.9%) |
343 ratings from 39 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Leerink Partners | Maintained | Outperform | $198 $205 | Sep 18, 2026 |
| RBC Capital | Reiterated | Sector Perform | $183 | Aug 20, 2026 |
| RBC Capital | Maintained | Sector Perform | $190 $183 | Aug 3, 2026 |
| Goldman Sachs | Maintained | Neutral | $242 $190 | Jul 30, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $212 $191 | Jul 29, 2026 |
| Guggenheim | Maintained | Buy | $195 $189 | Jul 29, 2026 |
| Cantor Fitzgerald | Reiterated | Neutral | $194 | Jul 29, 2026 |
| Baird | Maintained | Neutral | $204 $166 | Jul 29, 2026 |
| Cantor Fitzgerald | Reiterated | Neutral | $194 | Jul 28, 2026 |
| Barclays | Maintained | Equal-Weight | $179 $168 | Jul 28, 2026 |
| Guggenheim | Maintained | Buy | $211 $195 | Jul 20, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $165 $166 | Jul 13, 2026 |
| Barclays | Downgraded from Overweight | Equal-Weight | $179 | Jul 8, 2026 |
| TD Cowen | Maintained | Buy | $230 $197 | Jun 22, 2026 |
| UBS | Maintained | Buy | $320 $310 | Apr 30, 2026 |
| TD Cowen | Maintained | Buy | $245 $230 | Apr 29, 2026 |
| RBC Capital | Changed from Sector Performer | Sector Perform | $216 $190 | Apr 29, 2026 |
| Guggenheim | Maintained | Buy | $238 $211 | Apr 29, 2026 |
| Cantor Fitzgerald | Maintained | Neutral | $229 $194 | Apr 29, 2026 |
| Baird | Maintained | Neutral | $241 $204 | Apr 29, 2026 |
| Barclays | Maintained | Overweight | $268 $238 | Apr 28, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $235 $212 | Mar 2, 2026 |
| Cantor Fitzgerald | Maintained | Neutral | $250 $229 | Feb 27, 2026 |
| Barclays | Maintained | Overweight | $262 $268 | Feb 26, 2026 |
| Barclays | Maintained | Overweight | $263 $262 | Jan 22, 2026 |
54 filings from 10 insiders · 0 buy / 0 sell over 6m
Officers and directors of UHS, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SUSSMAN ELLIOT M.D.Director | Grant | 1.2k | — | — | May 20, 2026 |
| SINGER MARIA RUDERMANDirector | Grant | 1.2k | — | — | May 20, 2026 |
| CHEN-LANGENMAYR NINADirector | Grant | 1.2k | — | — | May 20, 2026 |
| MCDONNELL EILEEN C.Director | Grant | 1.2k | — | — | May 20, 2026 |
| NIMETZ WARREN J.Director | Grant | 1.2k | — | — | May 20, 2026 |
| FILTON STEVEN G.Chief Financial Officer | Grant | 6.8k | — | — | Mar 26, 2026 |
| PETERSON MATTHEW JAYOfficer | Grant | 5.6k | — | — | Mar 26, 2026 |
| SIM EDWARD H.Officer | Grant | 6.4k | — | — | Mar 26, 2026 |
| MILLER MARC DChief Executive Officer | Grant | 29.7k | — | — | Mar 26, 2026 |
| MILLER ALAN BOfficer, Director and Beneficial Owner | Grant | 14.2k | — | — | Mar 26, 2026 |
| SUSSMAN ELLIOT M.D.Director | Exercise | 2.5k | $138.80 | $347k | Mar 13, 2026 |
| SUSSMAN ELLIOT M.D.Director | Sell | 674 | $186.35 | $128k | Mar 13, 2026 |
| MILLER ALAN BOfficer, Director and Beneficial Owner | Grant | 33.1k | — | — | Mar 12, 2026 |
| MILLER MARC DChief Executive Officer | Grant | 63.0k | — | — | Mar 12, 2026 |
| SIM EDWARD H.Officer | Grant | 15.0k | — | — | Mar 12, 2026 |
| PETERSON MATTHEW JAYOfficer | Grant | 13.2k | — | — | Mar 12, 2026 |
| FILTON STEVEN G.Chief Financial Officer | Grant | 16.0k | — | — | Mar 12, 2026 |
| FILTON STEVEN G.Chief Financial Officer | Exercise | 83.2k | $138.80 | $12.16M | Mar 12, 2026 |
| MILLER MARC DChief Executive Officer | Exercise | 100.4k | $138.80 | $14.64M | Mar 12, 2026 |
| SINGER MARIA RUDERMANDirector | Exercise | 2.5k | $138.80 | $347k | Mar 12, 2026 |
No analyst notes on UHS yet.
Analyst Ratings
17 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 6 | 13 | 0 | 1 | Hold2.80 |
| 1 mo ago | 1 | 6 | 12 | 0 | 1 | Hold2.70 |
| 2 mo ago | 1 | 6 | 12 | 0 | 1 | Hold2.70 |
| 3 mo ago | 1 | 6 | 12 | 0 | 1 | Hold2.70 |
Members whose judged calls on UHS have played out most reliably.
No settled calls on UHS yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice